Using Constellation Pharmacology to Characterize a Novel α-Conotoxin from .

Journal: Marine drugs

Volume: 22

Issue: 3

Year of Publication: 2024

Affiliated Institutions:  Interdisciplinary Centre of Marine and Environmental Research (CIIMAR/CIMAR-LA), University of Porto, Terminal de Cruzeiros do Porto de Leixões, Avenida General Norton de Matos, S/N, - Matosinhos, Portugal. School of Biological Sciences, University of Utah, Salt Lake City, UT , USA. Departments of Biochemistry and Molecular Pharmacology, New York University Langone Medical Center, New York, NY , USA.

Abstract summary 

The venom of cone snails has been proven to be a rich source of bioactive peptides that target a variety of ion channels and receptors. α-Conotoxins (αCtx) interact with nicotinic acetylcholine receptors (nAChRs) and are powerful tools for investigating the structure and function of the various nAChR subtypes. By studying how conotoxins interact with nAChRs, we can improve our understanding of these receptors, leading to new insights into neurological diseases associated with nAChRs. Here, we describe the discovery and characterization of a novel conotoxin from , αCtx-AtIA, which has an amino acid sequence homologous to the well-described αCtx-PeIA, but with a different selectivity profile towards nAChRs. We tested the synthetic αCtx-AtIA using the calcium imaging-based Constellation Pharmacology assay on mouse DRG neurons and found that αCtx-AtIA significantly inhibited ACh-induced calcium influx in the presence of an α7 positive allosteric modulator, PNU-120596 (PNU). However, αCtx-AtIA did not display any activity in the absence of PNU. These findings were further validated using two-electrode voltage clamp electrophysiology performed on oocytes overexpressing mouse α3β4, α6/α3β4 and α7 nAChRs subtypes. We observed that αCtx-AtIA displayed no or low potency in blocking α3β4 and α6/α3β4 receptors, respectively, but improved potency and selectivity to block α7 nAChRs when compared with αCtx-PeIA. Through the synthesis of two additional analogs of αCtx-AtIA and subsequent characterization using Constellation Pharmacology, we were able to identify residue Trp18 as a major contributor to the activity of the peptide.

Authors & Co-authors:  Neves Urcino Chase Dowell Hone Morgenstern Chua Ramiro Imperial Leavitt Phan Fisher Watkins Raghuraman Tun Ueberheide McIntosh Vasconcelos Olivera Gajewiak

Study Outcome 

Source Link: Visit source

Statistics
Citations :  Lewis R.J., Dutertre S., Vetter I., Christie M.J. Conus Venom Peptide Pharmacology. Pharmacol. Rev. 2012;64:259–298. doi: 10.1124/pr.111.005322.
Authors :  20
Identifiers
Doi : 118
SSN : 1660-3397
Study Population
Male,Female
Mesh Terms
Animals
Other Terms
Constellation Pharmacology;DRG neurons;conotoxin;nAChRs
Study Design
Study Approach
Country of Study
Publication Country
Switzerland